Grastek Tablet
NDC Package 52709-1501-5
Package Information
Grastek (timothy grass pollen allergen extract) tablets is a medication used to treat certain allergies that may occur seasonally or year round. This formulation utilizes a tablet delivery system. Marketed by Alk-abello A S, this product is identified by NDC 52709-1501 and is authorized under FDA application BLA125473.
Identification & Billing
- RxCUI: 1495309 - Timothy grass pollen extract 2800 BAU Sublingual Tablet
- RxCUI: 1495316 - Grastek 2800 BAU Sublingual Tablet
- RxCUI: 1495316 - Timothy grass pollen extract 2800 BAU Sublingual Tablet [Grastek]
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 52709 - Alk-abello A S
- 52709-1501 - Grastek
- 52709-1501-5 - 1 BLISTER PACK in 1 CARTON / 5 TABLET in 1 BLISTER PACK
- 52709-1501 - Grastek
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (52709-1501). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 52709-1501-5 identifies a specific commercial package of 1 blister pack in 1 carton / 5 tablet in 1 blister pack of Grastek, a standardized allergenic label labeled by Alk-abello A S. This tablet is formulated for sublingual use and contains phleum pratense pollen as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Alk-abello A S on April 11, 2014. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
This medication is used to treat certain allergies that may occur seasonally or year round. It is an extract of certain plant pollens that can cause allergies. Before prescribing this medication, your doctor must do laboratory/medical tests (such as skin or IgE tests) to learn what you are allergic to. This pollen allergen extract works by making your body less sensitive to the pollens (such as ragweed, grasses) that cause your allergies. This medication will not work right away to relieve allergy symptoms. When taken as directed, it may help relieve symptoms such as sneezing, runny/stuffy nose, cough, or itchy/watery eyes that are caused by allergies.
How is this Alk-abello A S product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 52709150105. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.